ClinicalTrials.gg
CompletedNCT00461305Updated Jan 24, 2013Results posted

Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea

A Phase 2/3 interventional study of DRSP 3 mg/EE 20 µg (13 cycles) and DRSP 3 mg/EE 30 µg (6 cycles) in Dysmenorrhea, sponsored by Bayer. Completed at 26 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-01-24.

Sponsored by Bayer · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Dysmenorrhea by Bayer — none open to participants now, none under way, none of them phase 3. Dysmenorrhea · Bayer.

Started
2007
with 2 others
Phase 2/3
2 of 11
none open now
Registered
1st of 11
by date

Among the 11 studies in Dysmenorrhea by Bayer, this one is one of 3 that started in 2007, is one of 2 in phase 2/3, and was the 1st registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

None of the 11 studies in Dysmenorrhea by Bayer is open now. The open studies under Dysmenorrhea, anywhere →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Dysmenorrhea by Bayer as a file.
02

Study summary

The purpose of this study is to investigate efficacy of ethinylestradiol for intracyclic bleeding profile in patients with dysmenorrhea and to investigate the long term safety

Read the detailed description

The "drospirenone 3 mg/ethinylestradiol 20 μg (13 cycles)" group is to be treated by oral administration for 52 weeks, 13 cycles. The "drospirenone 3 mg/ethinylestradiol 30 μg (6 cycles)" group is to be treated by oral administration for 24 weeks, 6 cycles.

The trial is sponsored by Bayer Yakuhin, Ltd.

03

Conditions studied

  • Dysmenorrhea

Browse trials for

Keywords

  • Dysmenorrhea
  • Intracyclic bleeding
  • Drospirenone (DRSP)
  • Ethinylestradiol
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 20 years or older at obtaining
  • Patients having the normal menstrual cycle (25 to 38 days) in the latest two menses before the final enrollment
  • Patients having a total dysmenorrheal score of at least 3 points in twice of the latest menstruation before the final enrollment

Exclusion criteria

Exclusion Criteria:

  • Patients with ovarian chocolate cysts
  • Patients with fibroid needed to be treated
  • Patients with estrogen-dependent tumors and patients with cervical cancer or suspected cervical cancer
  • Patients with undiagnosed abnormal vaginal bleeding
  • Patients with thrombophlebitis, pulmonary embolism, cerebrovascular disease, or coronary artery disease or a history of those diseases
  • Patients aged 35 years or older who smoke at least 15 cigarettes per day
  • Patients with migraine accompanied by prodromata
  • Patients with pulmonary hypertension or valvular heart disease
  • Patients who are regularly taking nutritional products that contain St. John's Wort
  • Patients who underwent surgical treatment for endometriosis within 2 months prior to screening
  • Patients who may need to regularly use analgesics for therapeutic objectives other than relief from the pain of dysmenorrhea during this study (occasional use permitted)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
420 participants (actual)

Study arms

  • Experimental
    DRSP 3 mg/EE 20 µg (13 cycles)

    1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)

    Drug: DRSP 3 mg/EE 20 µg (13 cycles)

  • Experimental
    DRSP 3 mg/EE 30 µg (6 cycles)

    1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)

    Drug: DRSP 3 mg/EE 30 µg (6 cycles)

Interventions

  • DrugDRSP 3 mg/EE 20 µg (13 cycles)

    Drug page: Drospirenone

    1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)

  • DrugDRSP 3 mg/EE 30 µg (6 cycles)

    Drug page: Drospirenone

    1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Intracyclic Bleeding at Cycle 6

    Intracyclic bleedings were defined as bleedings while a participant takes active tablets.

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

Secondary outcomes

  1. Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 6

    Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.

    Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle

  2. Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 13

    Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.

    Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle

  3. Distribution of Total Dysmenorrhea Score at Cycle 6

    Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  4. Distribution of Total Dysmenorrhea Score at Cycle 13

    Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  5. Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 6

    Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  6. Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 13

    Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  7. Distribution of Severity of Lumbago During Menstruation at Cycle 6

    Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  8. Distribution of Severity of Lumbago During Menstruation at Cycle 13

    Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  9. Distribution of Severity of Headache During Menstruation at Cycle 6

    Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  10. Distribution of Severity of Headache During Menstruation at Cycle 13

    Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  11. Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 6

    Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  12. Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 13

    Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  13. Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 6

    Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  14. Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 13

    Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  15. Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6

    VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).

    Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle

  16. Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13

    VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).

    Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle

  17. Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6

    VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).

    Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle

  18. Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13

    VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).

    Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle

  19. Number of Any Bleeding Episodes From Cycle 1 to Cycle 6

    Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  20. Number of Any Bleeding Episodes From Cycle 1 to Cycle 13

    Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  21. Number of Any Bleeding Days From Cycle 1 to Cycle 6

    Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  22. Number of Any Bleeding Days From Cycle 1 to Cycle 13

    Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 4 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  23. Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 6

    Intracyclic bleedings were defined as bleedings while a participant takes active tablets.

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  24. Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 13

    Intracyclic bleedings were defined as bleedings while a participant takes active tablets.

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  25. Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 6

    Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  26. Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 13

    Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  27. Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 6

    Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  28. Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 13

    Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  29. Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 6

    Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).

    Time frame: Up to Cycle 6 (168 days) with 28 days per cycle

  30. Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 13

    Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).

    Time frame: Up to Cycle 13 (364 days) with 28 days per cycle

  31. Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6

    CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.

    Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle

  32. Change in Serum CA-125 From Baseline to Cycle 13

    CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.

    Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle

  33. Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 6

    CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.

    Time frame: From baseline up to Cycle 6 (168 days) with 28 days per cycle

  34. Change in Serum CRP From Baseline to Cycle 13

    CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.

    Time frame: From baseline up to Cycle 13 (364 days) with 28 days per cycle

07

Results

Posted Oct 1, 2010

Participant flow

Treatment
Participant flow — Treatment
MilestoneDRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Started35565
Subjects dispensed drugs35065
Subjects received treatment34965
Completed25456
Not completed1019
Withdrew: Adverse event263
Withdrew: Lost to follow-up42
Withdrew: Protocol violation132
Withdrew: Withdrawal by subject482
Withdrew: Never dispensed50
Withdrew: Study drug not taken10
Withdrew: Partially missing diary20
Withdrew: Other (missing drug etc)20
Continued Treatment
Participant flow — Continued Treatment
MilestoneDRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Started3490
Completed2540
Not completed950
Withdrew: Adverse event260
Withdrew: Lost to follow-up40
Withdrew: Protocol violation130
Withdrew: Withdrawal by subject480
Withdrew: Partially missing diary20
Withdrew: Other (missing drug etc)20

Outcome measures

PrimaryNumber of Participants With Intracyclic Bleeding at Cycle 6

Intracyclic bleedings were defined as bleedings while a participant takes active tablets.

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Number of Participants With Intracyclic Bleeding at Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Number of Participants With Intracyclic Bleeding at Cycle 6404
Statistical analysis
  • DRSP 3 mg/EE 20 µg (6 Cycles) · Binominal parameter by exact method · Incidence on one treatment arm: 13.4 · 95% CI 9.73 to 17.77No group comparison were planned. Binomial parameter on each treatment arm was estimated by exact method.
  • DRSP 3 mg/EE 30 µg (6 Cycles) · Binominal parameter by exact method · Incidence on one treatment arm: 7.1 · 95% CI 1.98 to 17.29
SecondaryNumber of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 6

Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.

Time frame:
From baseline up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
-6 (change in total dysmenorrhea scores)52
-5 (change in total dysmenorrhea scores)223
-4 (change in total dysmenorrhea scores)418
-3 (change in total dysmenorrhea scores)7013
-2 (change in total dysmenorrhea scores)7110
-1 (change in total dysmenorrhea scores)3012
0 (change in total dysmenorrhea scores)254
1 (change in total dysmenorrhea scores)42
2 (change in total dysmenorrhea scores)40
3 (change in total dysmenorrhea scores)00
4 (change in total dysmenorrhea scores)00
5 (change in total dysmenorrhea scores)00
6 (change in total dysmenorrhea scores)00
SecondaryNumber of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 13

Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.). Changed total dysmenorrheal scores: -6 to -1 mean improvement, 1 to 6 mean worsening, 0 means no change.

Time frame:
From baseline up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · participants
Number of Participants With a Change in Total Dysmenorrhea Score From Baseline to Cycle 13
participantsDRSP 3 mg/EE 20 µg (13 Cycles)
-6 (change in total dysmenorrhea scores)4
-5 (change in total dysmenorrhea scores)22
-4 (change in total dysmenorrhea scores)47
-3 (change in total dysmenorrhea scores)68
-2 (change in total dysmenorrhea scores)44
-1 (change in total dysmenorrhea scores)32
0 (change in total dysmenorrhea scores)12
1 (change in total dysmenorrhea scores)11
2 (change in total dysmenorrhea scores)2
3 (change in total dysmenorrhea scores)0
4 (change in total dysmenorrhea scores)0
5 (change in total dysmenorrhea scores)0
6 (change in total dysmenorrhea scores)0
SecondaryDistribution of Total Dysmenorrhea Score at Cycle 6

Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Total Dysmenorrhea Score at Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
06513
17916
2499
3428
4193
5174
611
SecondaryDistribution of Total Dysmenorrhea Score at Cycle 13

Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Total Dysmenorrhea Score at Cycle 13
participantsDRSP 3 mg/EE 20 µg (13 Cycles)
073
166
241
324
424
513
61
SecondaryDistribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 6

Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
none7514
mild11919
moderate5916
severe195
SecondaryDistribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 13

Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Severity of Lower Abdominal Pain During Menstruation at Cycle 13
participantsDRSP 3 mg/EE 20 µg (13 Cycles)
none78
mild106
moderate47
severe11
SecondaryDistribution of Severity of Lumbago During Menstruation at Cycle 6

Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Severity of Lumbago During Menstruation at Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
none15421
mild8829
moderate262
severe42
SecondaryDistribution of Severity of Lumbago During Menstruation at Cycle 13

Severity of lumbago during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Severity of Lumbago During Menstruation at Cycle 13
participantsDRSP 3 mg/EE 20 µg (13 Cycles)
none148
mild72
moderate19
severe3
SecondaryDistribution of Severity of Headache During Menstruation at Cycle 6

Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Severity of Headache During Menstruation at Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
none18737
mild414
moderate2911
severe152
SecondaryDistribution of Severity of Headache During Menstruation at Cycle 13

Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Severity of Headache During Menstruation at Cycle 13
participantsDRSP 3 mg/EE 20 µg (13 Cycles)
none168
mild38
moderate30
severe6
SecondaryDistribution of Severity of Nausea or Vomiting During Menstruation at Cycle 6

Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
none25151
mild141
moderate42
severe30
SecondaryDistribution of Severity of Nausea or Vomiting During Menstruation at Cycle 13

Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · participants
Distribution of Severity of Nausea or Vomiting During Menstruation at Cycle 13
participantsDRSP 3 mg/EE 20 µg (13 Cycles)
none229
mild11
moderate2
severe0
SecondaryNumber of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 6

Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
020234
15213
2114
321
421
520
601
SecondaryNumber of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 13

Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · participants
Number of Participants With a Total Pelvic Pain Score of 0 up to 6 at Times Other Than During Menstruation at Cycle 13
participantsDRSP 3 mg/EE 20 µg (13 Cycles)
0177
149
212
32
42
50
60
SecondaryChange in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6

VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).

Time frame:
From baseline up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Mean · scores on a scale
Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6
scores on a scaleDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 6-37.2 (-91 to 47)-31.9 (-71 to 13)
SecondaryChange in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13

VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).

Time frame:
From baseline up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Mean · scores on a scale
Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13
scores on a scaleDRSP 3 mg/EE 20 µg (13 Cycles)
Change in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation From Baseline to Cycle 13-41.6 (-91 to 36)
SecondaryChange in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6

VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).

Time frame:
From baseline up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Mean · scores on a scale
Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 6
scores on a scaleDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 66.7 (0 to 80)12.2 (0 to 83)
SecondaryChange in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13

VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).

Time frame:
From baseline up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Mean · scores on a scale
Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 13
scores on a scaleDRSP 3 mg/EE 20 µg (13 Cycles)
Change in Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation From Baseline to Cycle 136.2 (0 to 65)
SecondaryNumber of Any Bleeding Episodes From Cycle 1 to Cycle 6

Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Mean · number of episodes
Number of Any Bleeding Episodes From Cycle 1 to Cycle 6
number of episodesDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Reference period 13.3 (1 to 7)3.4 (1 to 7)
Reference period 23.3 (0 to 10)3.1 (2 to 7)
SecondaryNumber of Any Bleeding Episodes From Cycle 1 to Cycle 13

Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Mean · number of episodes
Number of Any Bleeding Episodes From Cycle 1 to Cycle 13
number of episodesDRSP 3 mg/EE 20 µg (13 Cycles)
Reference period 13.2 (1 to 7)
Reference period 23.5 (0 to 10)
Reference period 33.1 (0 to 8)
Reference period 43.2 (0 to 8)
SecondaryNumber of Any Bleeding Days From Cycle 1 to Cycle 6

Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 3 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days).

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Mean · days
Number of Any Bleeding Days From Cycle 1 to Cycle 6
daysDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Reference period 130.7 (14 to 65)28.9 (13 to 65)
Reference period 219.3 (0 to 78)19.9 (9 to 42)
SecondaryNumber of Any Bleeding Days From Cycle 1 to Cycle 13

Vaginal bleeding was rated as none, spotting, light, normal, or heavy based on the participant's experience. A reference period is about 3 cycles (90 days): reference period 1 is from Cycle 1 to Cycle 4 (the 1st 90 days), reference period 2 is from Cycle 4 to Cycle 6 (the 2nd 90 days), reference period 3 is from Cycle 7 to Cycle 9 (the 3rd 90 days), reference period 4 is from Cycle 10 to Cycle 12 (the 4th 90 days).

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Mean · days
Number of Any Bleeding Days From Cycle 1 to Cycle 13
daysDRSP 3 mg/EE 20 µg (13 Cycles)
Reference period 130.6 (14 to 65)
Reference period 219.8 (0 to 79)
Reference period 321.2 (0 to 88)
Reference period 417.7 (0 to 69)
SecondaryNumber of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 6

Intracyclic bleedings were defined as bleedings while a participant takes active tablets.

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Cycle 19419
Cycle 2388
Cycle 3458
Cycle 4333
Cycle 5405
Cycle 6294
SecondaryNumber of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 13

Intracyclic bleedings were defined as bleedings while a participant takes active tablets.

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · participants
Number of Participants With Intracyclic Bleeding From Cycle 1 to Cycle 13
participantsDRSP 3 mg/EE 20 µg (13 Cycles)
Cycle 193
Cycle 238
Cycle 345
Cycle 433
Cycle 541
Cycle 640
Cycle 7114
Cycle 824
Cycle 924
Cycle 1024
Cycle 1121
Cycle 1223
Cycle 1331
SecondaryNumber of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 6

Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · participants
Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 6
participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Cycle 127654
Cycle 231057
Cycle 330258
Cycle 429054
Cycle 527954
Cycle 618552
SecondaryNumber of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 13

Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · participants
Number of Participants With Withdrawal Bleeding From Cycle 1 to Cycle 13
participantsDRSP 3 mg/EE 20 µg (13 Cycles)
Cycle 1274
Cycle 2314
Cycle 3307
Cycle 4295
Cycle 5289
Cycle 6285
Cycle 7229
Cycle 8259
Cycle 9245
Cycle 10250
Cycle 11246
Cycle 12243
Cycle 13241
SecondaryPercentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 6

Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · Percentage of participants
Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 6
Percentage of participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Cycle 190.389.5
Cycle 297.4100.0
Cycle 391.1100.0
Cycle 487.9100.0
Cycle 587.880.0
Cycle 692.5100.0
SecondaryPercentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 13

Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · Percentage of participants
Percentage of Participants With Non-heavy Intracyclic Bleeding From Cycle 1 to Cycle 13
Percentage of participantsDRSP 3 mg/EE 20 µg (13 Cycles)
Cycle 190.3
Cycle 297.4
Cycle 391.1
Cycle 487.9
Cycle 587.8
Cycle 692.5
Cycle 790.4
Cycle 8100.0
Cycle 987.5
Cycle 10100.0
Cycle 11100.0
Cycle 12100.0
Cycle 1390.3
SecondaryPercentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 6

Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).

Time frame:
Up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Number · Percentage of participants
Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 6
Percentage of participantsDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Cycle 190.187.0
Cycle 290.894.7
Cycle 391.287.9
Cycle 492.292.6
Cycle 592.788.9
Cycle 690.988.5
SecondaryPercentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 13

Non-heavy bleeding was defined as those other than heavy bleeding (i.e. spotting, light, or normal bleeding).

Time frame:
Up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Number · Percentage of participants
Percentage of Participants With Non-heavy Withdrawal Bleeding From Cycle 1 to Cycle 13
Percentage of participantsDRSP 3 mg/EE 20 µg (13 Cycles)
Cycle 190.1
Cycle 290.8
Cycle 391.2
Cycle 492.2
Cycle 592.7
Cycle 690.9
Cycle 791.3
Cycle 891.1
Cycle 991.0
Cycle 1090.8
Cycle 1191.9
Cycle 1293.8
Cycle 1393.8
SecondaryChange in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6

CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.

Time frame:
From baseline up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Mean · Units/mL
Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6
Units/mLDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Change in Serum Carbohydrate Antigen-125 (CA-125) From Baseline to Cycle 6-4.33 (-134.8 to 46.1)-5.50 (-102.6 to 3.2)
SecondaryChange in Serum CA-125 From Baseline to Cycle 13

CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.

Time frame:
From baseline up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Mean · Units/mL
Change in Serum CA-125 From Baseline to Cycle 13
Units/mLDRSP 3 mg/EE 20 µg (13 Cycles)
Change in Serum CA-125 From Baseline to Cycle 13-4.66 (-135.5 to 90.0)
SecondaryChange in Serum C-reactive Protein (CRP) From Baseline to Cycle 6

CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.

Time frame:
From baseline up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Mean · mg/dL
Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 6
mg/dLDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
Change in Serum C-reactive Protein (CRP) From Baseline to Cycle 60.159 (-0.83 to 7.98)0.000 (-1.62 to 1.37)
SecondaryChange in Serum CRP From Baseline to Cycle 13

CRP is a laboratory parameter giving an indication of inflammation, whose elevated level suggests a potential inflammation.

Time frame:
From baseline up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Mean · mg/dL
Change in Serum CRP From Baseline to Cycle 13
mg/dLDRSP 3 mg/EE 20 µg (13 Cycles)
Change in Serum CRP From Baseline to Cycle 130.014 (-0.90 to 1.99)
Post-hocChange in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 6

Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

Time frame:
Baseline and up to Cycle 6 (168 days) with 28 days per cycle
Reported as:
Mean · scores on a scale
Change in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 6
scores on a scaleDRSP 3 mg/EE 20 µg (6 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
age: < 30 years-2.4 ± 1.68-2.2 ± 1.64
age: >= 30 years-2.2 ± 1.52-2.1 ± 1.69
weight: < 50 kg-2.0 ± 1.58-2.3 ± 1.76
weight: >= 50kg-2.5 ± 1.61-2.0 ± 1.60
functional dysmenorrhea-2.4 ± 1.64-2.3 ± 1.54
organic dysmenorrhea-2.0 ± 1.45-1.3 ± 1.91
with medical surgical history-2.3 ± 1.61-2.0 ± 1.69
without medical surgical history-2.4 ± 1.54-2.4 ± 1.60
with previous medication-2.3 ± 1.61-2.1 ± 1.66
with pregnancy history-2.2 ± 1.67-2.1 ± 1.68
with birth history-2.0 ± 1.71-2.4 ± 1.83
total dysmenorrhea score at baseline 3/4-1.9 ± 1.37-1.9 ± 1.37
total dysmenorrhea score at baseline 5/6-3.0 ± 1.73-2.6 ± 2.04
Post-hocChange in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 13

Total dysmenorrhea score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.

Time frame:
Baseline and up to Cycle 13 (364 days) with 28 days per cycle
Reported as:
Mean · scores on a scale
Change in Total Dysmenorrhea Score at Final Evaluation in Subgroups (1): From Baseline to Cycle 13
scores on a scaleDRSP 3 mg/EE 20 µg (13 Cycles)
age: < 30 years-2.5 ± 1.67
age: >= 30 years-2.4 ± 1.70
weight: < 50 kg-2.1 ± 1.68
weight: >= 50kg-2.7 ± 1.65
functional dysmenorrhea-2.6 ± 1.70
organic dysmenorrhea-2.1 ± 1.59
with medical surgical history-2.5 ± 1.72
without medical surgical history-2.5 ± 1.64
with previous medication-2.5 ± 1.69
with pregnancy history-2.1 ± 1.75
with birth history-1.9 ± 1.76
total dysmenorrhea score at baseline 3/4-2.0 ± 1.48
total dysmenorrhea score at baseline 5/6-3.2 ± 1.75

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DRSP 3 mg/EE 20 µg (13 Cycles)—5/355 (1.4%)335/355 (94.4%)
DRSP 3 mg/EE 30 µg (6 Cycles)—0/65 (0%)63/65 (96.9%)
Most frequent serious events
Most frequent serious events
EventDRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
AppendicitisInfections and infestations1/3550/65
DysmenorrhoeaReproductive system and breast disorders1/3550/65
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3550/65
Facial palsyNervous system disorders1/3550/65
Enteritis infectiousInfections and infestations1/3550/65
Most frequent other events
Showing 10 of 25
Most frequent other events
EventDRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)
HeadacheNervous system disorders215/35539/65
NasopharyngitisInfections and infestations182/35534/65
NauseaGastrointestinal disorders128/35525/65
DysmenorrhoeaReproductive system and breast disorders124/35520/65
MetrorrhagiaReproductive system and breast disorders97/3559/65
Genital haemorrhageReproductive system and breast disorders97/35514/65
Coagulation test abnormalInvestigations70/35512/65
Post procedural haemorrhageInjury, poisoning and procedural complications55/35511/65
Abdominal pain lowerGastrointestinal disorders53/3555/65
Plasminogen increasedInvestigations18/3557/65

Baseline characteristics

Age Continuous
Age Continuous(years)DRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)Total
Mean29.0 (20 to 44)30.9 (20 to 43)29.3 (20 to 44)
Sex: Female, Male
Sex: Female, Male(Participants)DRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)Total
Female34965414
Male000
Diagnosis type
Diagnosis type(participants)DRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)Total
Functional dysmenorrhea27353326
Organic dysmenorrhea761288
Details of organic dysmenorrhea
Details of organic dysmenorrhea(participants)DRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)Total
Endometriosis24428
Uterine fibroids27734
Uterine adenomyosis35843
Endometrial polyp101
Bicornuate uterus303
Multiple endometrial polyp101
Uterine enlargement101
Average length of menstrual cycle
Average length of menstrual cycle(days)DRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)Total
Mean29.5 (25 to 38)29.5 (25 to 38)29.5 (25 to 38)
Body Mass Index
Body Mass Index(kg/m^2)DRSP 3 mg/EE 20 µg (13 Cycles)DRSP 3 mg/EE 30 µg (6 Cycles)Total
Mean20.73 (16.2 to 29.9)20.56 (15.3 to 28.7)20.70 (15.3 to 29.9)
08

Study locations

26 sites
  • Nagoya, Aichi 460-0007, Japan
  • Nagoya, Aichi 460-0011, Japan
  • Nagoya, Aichi 464-0066, Japan
  • Maebashi, Gunma 371-0024, Japan
  • Takasaki, Gunma 370-0883, Japan
  • Kobe, Hyogo 650-0021, Japan
  • Nishinomiya, Hyogo 663-8204, Japan
  • Yamato, Kanagawa 242-0007, Japan
  • Yokohama, Kanagawa 231-0861, Japan
  • Sendai, Miyagi 980-0021, Japan
  • Sendai, Miyagi 981-0933, Japan
  • Sendai, Miyagi 984-0042, Japan
  • Toyonaka, Osaka 560-0022, Japan
  • Chuo-ku, Tokyo 104-0061, Japan
  • Hachioji, Tokyo 192-0046, Japan
  • Machida, Tokyo 194-0022, Japan
  • Musashino, Tokyo 180-0003, Japan
  • Ota-ku, Tokyo 144-0052, Japan
  • Setagaya-ku, Tokyo 156-0042, Japan
  • Setagaya-ku, Tokyo 157-0066, Japan
  • Shibuya-ku, Tokyo 150-0013, Japan
  • Shinagawa-ku, Tokyo 140-0013, Japan
  • Suginami-ku, Tokyo 167-0051, Japan
  • Toshima-ku, Tokyo 171-0021, Japan
  • Osaka, 530-0013, Japan
  • Osaka, 534-0014, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Jan 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2007
First posted
Apr 18, 2007
Start
Feb 2007
Primary completionActual
Jan 2009
CompletionActual
Aug 2009
Results first posted
Oct 1, 2010
Last update
Jan 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00461305
Lead sponsor
Bayer
First posted
Apr 18, 2007
Start date
Feb 2007
Primary completion
Jan 2009
Completion
Aug 2009
Results posted
Oct 1, 2010
Last update
Jan 24, 2013

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drospirenone

Start the discussion